Payment overview · 2025
General Payments
$962.42
49 reported records · 16 companies
Healthcare provider profile · identity verified
Nam Phan Ho, M.D
Allopathic & Osteopathic Physicians|Family Medicine · HOUSTON, TX · NPI 1730344185
Verified facts
What the public records show
CMS Open Payments records show Nam Phan Ho, M.D received $962.42 in general payments during 2025 across 49 reported records.
Amgen Inc. accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Gemtesa, Jardiance, Ozempic, Paxlovid, Shingrix.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $233.49 | 24.3% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.97 | 11.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.63 | 8.6% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $81.59 | 8.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.63 | 7.5% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$62.44 | 6.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.79 | 5.1% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.72 | 4.8% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $43.79 | 4.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $42.89 | 4.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.05 | 4.0% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.05 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.85 | 2.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.73 | 2.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.71 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.09 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $962.42 | 49 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $146.98 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $146.98 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $108.97 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $81.59 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $80.19 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $62.81 | 4 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $62.44 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $48.79 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $48.79 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $48.15 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $48.15 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $48.15 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $45.72 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.89 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.05 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $37.69 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 43 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 90 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 32 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 122 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 194 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 41 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
39 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
90 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 38 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
26 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
194 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
43 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2228 | 720 |
| Losartan Potassium | Losartan Potassium | 1290 | 428 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1061 | 345 |
| Amlodipine Besylate | Amlodipine Besylate | 957 | 326 |
| Metformin Hcl | Metformin Hcl | 910 | 290 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 793 | 323 |
| Donepezil Hcl | Donepezil Hcl | 717 | 231 |
| Metoprolol Succinate | Metoprolol Succinate | 603 | 197 |
| Omeprazole | Omeprazole | 552 | 212 |
| Famotidine | Famotidine | 538 | 216 |
| Gabapentin | Gabapentin | 534 | 208 |
| Simvastatin | Simvastatin | 494 | 153 |
| Alendronate Sodium | Alendronate Sodium | 448 | 159 |
| Lisinopril | Lisinopril | 428 | 143 |
| Carvedilol | Carvedilol | 400 | 129 |
| Finasteride | Finasteride | 361 | 119 |
| Fluticasone Propionate | Fluticasone Propionate | 352 | 136 |
| Pregabalin | Pregabalin | 337 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 329 | 110 |
| Allopurinol | Allopurinol | 320 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 108 |
| Clopidogrel | Clopidogrel Bisulfate | 285 | 96 |
| Montelukast Sodium | Montelukast Sodium | 284 | 109 |
| Diclofenac Sodium | Diclofenac Sodium | 272 | 143 |
| Januvia | Sitagliptin Phosphate | 263 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 92 |
| Glipizide Er | Glipizide | 248 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 245 | 75 |
| Azithromycin | Azithromycin | 242 | 210 |
| Glimepiride | Glimepiride | 206 | 61 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 205 | 132 |
| Ozempic | Semaglutide | 194 | 40 |
| Tramadol Hcl | Tramadol Hcl | 185 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 57 |
| Vascepa | Icosapent Ethyl | 172 | 54 |
| Mirtazapine | Mirtazapine | 169 | 58 |
| Ibuprofen | Ibuprofen | 167 | 135 |
| Memantine Hcl | Memantine Hcl | 157 | 61 |
| Sertraline Hcl | Sertraline Hcl | 155 | 53 |
| Trazodone Hcl | Trazodone Hcl | 152 | 52 |
| Glipizide | Glipizide | 147 | 51 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 146 | 49 |
| Celecoxib | Celecoxib | 131 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 46 |
| Pioglitazone Hcl | Pioglitazone Hcl | 124 | 47 |
| Fenofibrate | Fenofibrate | 122 | 44 |
| Jardiance | Empagliflozin | 122 | 38 |
| Doxazosin Mesylate | Doxazosin Mesylate | 119 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 35 |
| Ammonium Lactate | Ammonium Lactate | 107 | 57 |
| Azelastine Hcl | Azelastine Hcl | 105 | 37 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 104 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 37 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 102 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 36 |
| Ezetimibe | Ezetimibe | 98 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 98 | 31 |
| Furosemide | Furosemide | 96 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 42 |
| Loperamide | Loperamide Hcl | 96 | 91 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 92 | 27 |
| Farxiga | Dapagliflozin Propanediol | 90 | 33 |
| Alprazolam | Alprazolam | 83 | 11 |
| Meclizine Hcl | Meclizine Hcl | 80 | 32 |
| Nifedipine Er | Nifedipine | 79 | 24 |
| Valsartan | Valsartan | 75 | 21 |
| Atenolol | Atenolol | 72 | 23 |
| Methylprednisolone | Methylprednisolone | 70 | 65 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 68 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 26 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 64 | 25 |
| Trulicity | Dulaglutide | 64 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 63 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 26 |
| Colchicine | Colchicine | 58 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | 20 |
| Eliquis | Apixaban | 57 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 57 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 23 |
| Sildenafil Citrate | Sildenafil Citrate | 51 | 19 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 12 |
| Creon | Lipase/Protease/Amylase | 49 | suppressed |
| Baclofen | Baclofen | 48 | 28 |
| Vemlidy | Tenofovir Alafenamide | 46 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 43 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 13 |
| Mometasone Furoate | Mometasone Furoate | 41 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 41 | 41 |
| Tradjenta | Linagliptin | 41 | 14 |
| Prolia | Denosumab | 39 | 28 |
| Lactulose | Lactulose | 37 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 36 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 29 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 34 |
| Lovastatin | Lovastatin | 35 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | 12 |
| Amoxicillin | Amoxicillin | 34 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 32 |
| Entecavir | Entecavir | 33 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Gemtesa | Vibegron | 32 | 12 |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 12 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 28 | suppressed |
| Levemir Flextouch | Insulin Detemir | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 25 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 26 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 23 |
| Lorazepam | Lorazepam | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | 13 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 11 |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 22 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Humulin R | Insulin Regular, Human | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Ciclopirox | Ciclopirox | 17 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Proctozone-Hc | Hydrocortisone | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 13 | 11 |
| Clonazepam | Clonazepam | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $962.42 · 49 records | Amgen Inc. | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KISUNLA, KRYSTEXXA, Leqembi, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, Rybelsus, SHINGRIX, ZENPEP, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error